Author Correction: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway

Chao Fang; Yi-Xin Chen; Na-Yiyuan Wu; Ji-Ye Yin; Xiang-Ping Li; Hsuan-Shun Huang; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu

doi:10.1038/s41598-021-01417-w

Author Correction: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway

Sci Rep. 2021 Nov 11;11(1):22452. doi: 10.1038/s41598-021-01417-w.

Authors

Chao Fang^{1

2}, Yi-Xin Chen^{1

2}, Na-Yiyuan Wu^{1

2}, Ji-Ye Yin^{1

2}, Xiang-Ping Li³, Hsuan-Shun Huang⁴, Wei Zhang^{1

2}, Hong-Hao Zhou^{1

2

5}, Zhao-Qian Liu^{6

7

8}

Affiliations

¹ Departments of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
² Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, P. R. China.
³ Departments of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
⁴ Department of Research, Cervical Cancer Prevention Center, Tzu Chi University, Hualien, 970, Taiwan, Republic of China.
⁵ Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, 421001, P. R. China.
⁶ Departments of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China. liuzhaoqian63@126.com.
⁷ Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, P. R. China. liuzhaoqian63@126.com.
⁸ Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, 421001, P. R. China. liuzhaoqian63@126.com.

No abstract available

Publication types

Published Erratum